Emerging therapeutic drugs for AML. - Wikidata - wikimedia - TriplyDB

Emerging therapeutic drugs for AML.

Emerging therapeutic drugs for AML.

http://www.wikidata.org/entity/Q38667491

about

Synthetic lethality in lung cancer and translation to clinical therapies Future prospects of therapeutic clinical trials in acute myeloid leukemia.Is it possible to cure childhood acute myeloid leukaemia without significant cardiotoxicity?The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.Emerging therapies for acute myeloid leukemia.Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate A Standardized Chemically Modified Curcuma longa Extract Modulates IRAK-MAPK Signaling in Inflammation and Potentiates Cytotoxicity.Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Isocitrate dehydrogenase mutations in myeloid malignancies.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease.Interferon-γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells.The cancer epigenome: Concepts, challenges, and therapeutic opportunities.The development of targeted new agents to improve the outcome for children with leukemia.Pharmacologic maintenance strategies following allogeneic hematopoietic cell transplantation for acute myeloid leukemia.Molecular landscape in acute myeloid leukemia: where do we stand in 2016 Treatment of Relapsed/Refractory Acute Myeloid Leukemia.Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML.FMS-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD): a villain among others.A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators A new target for differentiation therapy in AML.Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach.The rocky road to personalized medicine in acute myeloid leukaemia.Murine Retrovirally-Transduced Bone Marrow Engraftment Models of MLL-Fusion-Driven Acute Myelogenous Leukemias (AML).KRAS oncoprotein expression is regulated by a self-governing eIF5A-PEAK1 feed-forward regulatory loop.Precision therapy for acute myeloid leukemia.Improved outcome for AML patients over the years 2000-2014.Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report.Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways.Mixed-Lineage Leukemia Fusions and Chromatin in Leukemia.Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia.Early mortality and survival in older adults with acute myeloid leukemia Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States

P2860

Q28072904-DD9520AF-F051-49A7-B67B-B8B99FC0B58F Q30244168-35A16E08-0054-4D07-8873-CA2D9253C89E Q30244600-3875D01F-70E1-42DE-B055-2036ADA151B0 Q30252512-96D8C037-B7A9-41C5-BB71-24201C894042 Q33576363-8D7C4B73-084B-40D3-9E72-585BAEDB4B7B Q33643108-61757B37-85F7-4517-966B-2C4F6F503B79 Q33739302-6DEAF3FE-A84F-4BF2-9424-38EFB9C300C6 Q37122453-8F77C097-0D89-4F32-B95C-072D62284186 Q37607838-73879ABA-F312-4C3F-ADF8-5A311C1C4AAA Q37615574-61EEF71A-994B-4AC7-A754-B88A77883B67 Q37624593-74750110-11C6-4623-87A0-5BD7ACEAF64E Q37625630-7C055985-C701-4F45-BF90-757A497E6958 Q38664735-1D09925B-1C16-4808-94C3-3573C98862F6 Q38721210-7F90B731-1765-4E81-854F-BC8C51C98993 Q38736778-7ABFB74F-77DD-402A-8EBC-D2F58D47C602 Q38743881-7886A2BF-26F9-4567-8EAC-DB51E13437D4 Q38964974-A6185EAD-D49F-42DA-AAEA-A33929300D60 Q38967853-DD73B15C-99D3-4276-ACE7-541BBE1CD673 Q39116878-2A4583F6-1CB8-4025-BD18-DB3A0B8E119D Q39175665-EA3D06B5-F3C9-46BE-8817-9EE925604162 Q39475165-99693317-5623-4F1C-8E1B-D03490E7F64C Q42349214-834BF15B-71C2-4253-9797-0EE330A88529 Q42764236-8CF11EFA-538D-4164-B516-5B9614DE4757 Q47124303-E10E4C2D-7A65-4AF5-B310-CBB54F352690 Q47136441-DA5CA3F9-F0AD-4FC3-A59C-3B0568049329 Q47304377-6C826BBF-ABCE-47DC-A3FA-FA48DA360FD7 Q47561008-CBCA6C1C-71BD-442F-A8EF-BB4CA7054C83 Q47823347-564BE548-8AF4-408F-8805-2AFBCB322636 Q48542758-F65D9677-DF08-4333-8C01-55ACEC686672 Q49534332-2E5B6483-3153-48CD-841D-E17268888207 Q49566124-72B4C9B1-B9EA-428F-8A2A-2CC27C387C45 Q49668289-8AE696F5-E31B-402D-AA81-D1FF459BA6B1 Q49957074-498086FE-5DE3-47D7-8FE4-0F8491B483E0 Q50453702-C76BB2FD-281E-476A-8778-2543B92E5F92 Q55433291-6FD13D39-0217-46E8-8E02-ECFD9AEC6450 Q57301977-6696652E-4E98-4F63-B974-9BE36742F826 Q58706473-A3FEB4A1-1238-4D75-ABD5-820C351248AC

P2860

Emerging therapeutic drugs for AML.

http://www.wikidata.org/entity/Q38667491

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Emerging therapeutic drugs for AML.

@en

type

label

Emerging therapeutic drugs for AML.

@en

prefLabel

Emerging therapeutic drugs for AML.

@en

P1433

Q38667491-34E5897C-4713-44A2-833B-C262C4135197

P1476

Q38667491-A3F80EA7-1655-4E65-AE78-849089C967DD

P2093

Q38667491-98057AAA-CBE8-4C3A-82A4-45881DD665C9

P2860

Q38667491-0277D688-7E44-456D-9674-5CD50C21351D

Q38667491-06BFF2A6-D841-40F1-8896-49B3E090ADFF

Q38667491-095C5763-3F1A-4672-B694-19B6A7C11E23

Q38667491-133C7573-EB79-4736-B8DA-ACA73046AAB4

Q38667491-13F08BF4-5276-4D38-9DED-EEB68E692E84

Q38667491-1BACDBD9-56E5-4653-A77C-CD93970CCB87

Q38667491-1FCCC917-84D2-4F0B-8D30-C9B74D1711B9

Q38667491-2F2BC9F0-4DAE-476A-B777-69B7CEF9B4C3

Q38667491-30E7B9A1-0A18-4933-975F-C8DBB498672F

Q38667491-33F65EBD-7069-42AD-8CA7-1F02600BFC64

P304

Q38667491-DA539D9B-AFDE-4389-8D37-1F2D27B5E90F

P31

Q38667491-E9CEA89C-6401-4E49-B50A-AB6C0E6BDE5A

P356

Q38667491-13315595-924C-4A29-9E71-801180221DCC

P407

Q38667491-A30AA8B4-E82D-463D-9413-2CC8FDA3DB4D

P433

Q38667491-1F52544E-D3D3-4047-91BB-695EEFD6E0F5

P478

Q38667491-F88A2616-19B9-465B-83E0-A73D608D9709

P50

Q38667491-8B62378E-9337-4E6E-AA0E-7EBA71707198

P577

Q38667491-ECE05A78-BDB0-4EE1-A5BA-B7DA8C6C585F

P5875

Q38667491-612A3FF0-8AE7-48C9-A1B9-3B0313E48251

P698

Q38667491-8978346D-D45C-45A2-A487-CC6CB41C061B

P932

Q38667491-450BEC70-D467-4F7E-A995-30A99AC8165B

P356

BLOOD-2015-07-604538

P1433

P1476

Emerging therapeutic drugs for AML.

@en

P2093

Eytan M Stein

http://www.w3.org/2001/XMLSchema#string

P2860

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.

Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia

IDH mutation impairs histone demethylation and results in a block to cell differentiation

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

P304

71-78

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2015-07-604538

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P50

Martin S Tallman

P577

2015-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

286511728

http://www.w3.org/2001/XMLSchema#string

P698

26660428

http://www.w3.org/2001/XMLSchema#string

P932

4915807

http://www.w3.org/2001/XMLSchema#string